SINOVAC BIOTECH LTD SVA
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.83
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $386.0M | $361.4M | $470.2M | $1.47B | $19.37B | $510.6M | $246.1M | $229.7M | $174.3M | $72.4M |
| Cost of revenue | $124.0M | $140.7M | $146.9M | $658.2M | $988.9M | $67.2M | $32.5M | $24.7M | $20.2M | $22.4M |
| Gross profit | $262.0M | $220.7M | $323.3M | $815.2M | $18.38B | $443.4M | $213.6M | $204.9M | $154.1M | $50.0M |
| R&D | $216.2M | $270.7M | $350.2M | $478.7M | $152.7M | $48.8M | $24.3M | $21.9M | $20.5M | $12.6M |
| SG&A | $333.0M | $420.9M | $598.2M | $836.1M | $602.1M | $176.5M | $121.5M | $137.0M | $87.4M | $42.0M |
| Total operating expenses | $752.1M | $726.2M | $1.04B | $1.32B | $758.1M | $227.8M | $145.0M | $159.6M | $108.7M | $49.5M |
| Operating income | -$490.1M | -$505.5M | -$714.0M | -$509.0M | $17.62B | $215.6M | $68.6M | $45.3M | $45.4M | $504.0K |
| Pre-tax income | -$262.1M | $42.8M | -$84.5M | -$48.5M | $17.57B | $216.6M | $70.8M | $46.6M | $45.0M | -$394.0K |
| Income tax | $63.3M | $2.2M | $36.4M | $11.5M | $3.45B | $31.4M | $5.6M | $10.5M | $8.3M | $2.7M |
| Net income | -$198.8M | $40.7M | -$120.9M | $14.5M | $8.12B | $110.4M | $44.9M | $21.8M | $25.8M | -$596.0K |
| EPS, basic | -0.83 | 1.27 | -0.19 | 0.20 | 113.54 | 1.06 | 0.42 | 0.34 | 0.45 | -0.01 |
| EPS, diluted | -0.83 | 1.27 | -0.19 | 0.20 | 113.44 | 0.97 | 0.41 | 0.34 | 0.45 | -0.01 |
| Shares, diluted (wtd. avg.) | $71.9M | $71.9M | $71.9M | $71.8M | $71.6M | $113.7M | $109.7M | $65.0M | $57.1M | $56.9M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $488.2M | $335.3M | $1.13B | $3.89B | $11.61B | $1.05B | $155.9M | $158.2M | $116.0M | $65.4M |
| Short-term investments | $5.48B | $9.61B | $9.89B | $6.65B | $1.81B | $135.2M | $50.3M | $18.9M | — | — |
| Receivables | $286.3M | $300.9M | $424.9M | $486.6M | $942.7M | $253.5M | $113.7M | $74.5M | $66.2M | $49.8M |
| Inventory | $94.3M | $96.9M | $135.6M | $175.3M | $391.1M | $105.8M | $27.8M | $25.1M | $19.6M | $14.1M |
| Total current assets | $7.06B | $10.64B | $11.60B | $11.30B | $14.94B | $1.56B | $349.6M | $284.2M | $203.9M | $130.7M |
| Property, plant and equipment | $706.1M | $881.0M | $952.0M | $989.7M | $855.0M | $200.4M | $74.3M | $70.9M | $76.4M | $66.9M |
| Goodwill | $12.6M | $27.5M | $0 | $0 | $0 | — | — | — | — | — |
| Other intangibles | $77.7M | $122.6M | $8.5M | $9.7M | $1.5M | $1.5M | — | — | — | — |
| Total assets | $8.54B | $12.34B | $13.61B | $14.03B | $16.76B | $1.90B | $452.3M | $369.8M | $299.2M | $211.4M |
| Accounts payable | $604.7M | $803.0M | $989.2M | $924.7M | $1.03B | $211.4M | $58.9M | $50.0M | $59.4M | $25.0M |
| Short-term debt | — | — | — | — | — | — | — | $3.3M | $18.2M | $31.3M |
| Total current liabilities | $1.54B | $1.45B | $1.29B | $1.26B | $2.52B | $679.6M | $87.2M | $58.2M | $92.5M | $66.3M |
| Long-term debt | $494.9M | $375.8M | $253.9M | $11.8M | $15.8M | $35.1M | $5.9M | $7.2M | $33.0M | $40.7M |
| Total liabilities | $2.15B | $2.04B | $1.97B | $1.79B | $3.21B | $781.2M | $100.1M | $77.9M | $122.1M | $81.7M |
| Retained earnings | $2.82B | $6.84B | $6.79B | $6.80B | $6.81B | $144.2M | $56.7M | $23.8M | $9.1M | -$11.9M |
| Total equity | $4.44B | $8.26B | $11.64B | $12.24B | $9.00B | $1.13B | $352.2M | $291.9M | $177.1M | $129.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$512.2M | -$56.9M | $138.6M | -$798.1M | $15.32B | $479.3M | $39.1M | $7.9M | $59.8M | -$13.9M |
| Depreciation and amortisation | $97.4M | $110.2M | $157.4M | $152.7M | $85.1M | $3.7M | $4.6M | $4.9M | $4.6M | $5.1M |
| Stock-based compensation | — | $0 | $0 | $0 | $7.7M | $10.2M | $3.0M | $4.3M | $979.0K | $2.4M |
| Capital expenditure | $48.9M | $96.0M | $156.2M | $313.9M | $594.2M | $0 | $10.6M | $5.6M | $11.9M | $12.7M |
| Investing cash flow | $4.39B | $456.4M | -$2.70B | -$6.09B | -$2.98B | -$204.8M | -$42.5M | -$25.3M | -$11.9M | -$11.8M |
| Financing cash flow | -$3.43B | -$824.0M | -$88.6M | -$299.5M | -$1.91B | $592.6M | $1.7M | $64.2M | -$1.3M | $27.8M |
| Dividends paid | $3.53B | $947.0M | $328.1M | $247.4M | $1.88B | $0 | $0 | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-258534.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |